The 2026 AAA-ICDR Life Sciences ADR Conference gathered 50 sector leaders at Ropes & Gray in Boston, MA, including in-house counsel, outside advocates, arbitrators, and industry executives.
The program focused on how dispute resolution must adapt to keep pace with fast-moving scientific innovation and regulatory demands in life sciences. Discussions covered how the sector balances unprecedented innovation with new risks, from supply chain breakdowns to AI arbitration tools.
A Program Designed for a Changing Industry
The conference covered broad trends in dispute resolution, practical arbitration strategies, and new ADR innovations.
- Emerging Dispute Trends: Panelists examined conflicts involving supply chains, co-development agreements, pricing pressures, data rights, IP ownership, milestone failures, confidentiality breaches, and cross-border enforcement — all intensified by regulatory oversight.
- Managing Complex International Arbitrations: Speakers addressed arbitrator selection, handling technical and scientific expert evidence, regulatory overlays, and enforcement challenges in multi-jurisdictional matters.
- Launching AAA-ICDR’s Dispute Review Board (DRB) Services: A key highlight was the introduction of life sciences-focused DRBs designed to prevent milestone disputes and governance deadlocks in long-term R&D collaborations.
- Clinical Trial & Data-Sharing Disputes: Discussions covered dataset control, disclosure demands, cybersecurity concerns, privacy frameworks, and the intersection of regulation and scientific standards.
- The Expanding Role of AI: The final session examined how AI is transforming both product development and dispute resolution — from AI-assisted document review and predictive analytics to draft award preparation and blockchain-based authentication.
Across sessions, one theme was clear: dispute resolution in life sciences must be proactive, technologically fluent, and tailored to the sector’s unique pressures.
Three Key Takeaways:
- Life Sciences Disputes Are More Complex, Global, and Regulatory-Driven Than Ever
Today’s disputes span licensing, IP ownership, pricing, supply chain resilience, and data integrity — often across borders and under heightened government scrutiny. International arbitrations increasingly require mastery of scientific testimony, regulatory frameworks, and complex technical evidence. As a result, success in life sciences ADR now demands more than contract expertise; arbitrators and counsel must also understand the underlying science, regulatory systems, and global enforcement dynamics to effectively manage high-stakes matters.
- Early Intervention Is No Longer Optional — It’s Strategic
The launch of AAA-ICDR’s Dispute Review Board services reflects a meaningful shift in the industry’s approach to conflict. Long-term R&D collaborations are particularly vulnerable to milestone disputes and governance stalemates that can stall innovation. DRBs provide a mechanism to address disagreements early — before they escalate into full arbitration or derail critical research — signaling a broader move from reactive dispute resolution to proactive risk management that protects innovation, preserves partnerships, and maintains business continuity.
- AI and Data Are Reshaping Both the Industry and Its Disputes
Artificial intelligence is accelerating drug development and diagnostics — and it’s transforming arbitration itself. Tools for AI-powered evidence review, predictive analytics, draft award preparation, and blockchain authentication are improving efficiency and accuracy in complex cases. At the same time, clinical trial and data-sharing disputes are raising difficult questions around dataset control, privacy, disclosure obligations, and scientific standards, making technological fluency essential for arbitrators and counsel tasked with managing information-heavy disputes while ensuring transparency and data integrity.
Looking Ahead
The conference made one point clear: dispute resolution must evolve alongside industry innovation to remain effective.
The future of life sciences ADR will be defined by:
- Proactive dispute prevention
- Sector-specific expertise
- Global enforceability
- Technological sophistication
AAA-ICDR is committed to providing innovative, tailored solutions. These help life sciences companies protect innovation and manage risk.